Michael R. McClung

Michael R. McClung

Auto-generated profile, based on publicly available information

Michael R. McClung

Oregon Osteoporosis Center, Portland, Oregon

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SCSteven R Cummings
Steven R Cummings
JMJavier San Martin
Javier San Martin
MMMichael R McClung
Michael R McClung
ESEthel S Siris
Ethel S Siris
RERichard Eastell
Richard Eastell
FTFreedom Trial
Freedom Trial
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis.

1 February 2001 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
MMMichael R. McClung
Michael R. McClung
PGPiet Geusens
Piet Geusens
PMPaul D. Miller
Paul D. Miller
HZHartmut Zippel
Hartmut Zippel
WBWilliam G. Bensen
William G. Bensen
JRJean-Yves Reginster
Jean-Yves Reginster
Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. We studied 5445 women 70 to 79 years old who had osteoporosis (indicated by a T score for bone mineral density at the femoral neck that was more than 4 SD below the mean peak value in young adults [–4] or lower than –3 plus a nonskeletal risk factor for hip fracture, such as poor gait or a propensity to fall) and 3886 women at least 80 years old who had at least one nonskeletal risk factor for hip fracture or low bone mineral density at the femoral neck (T score, lower than –4 or lower than –3 plus a hip-axis length of 11.1 cm or greater). The women were randomly assigned to receive treatment with oral risedronate (2.5 or 5.0 mg daily) or placebo for three years. The primary end point was the occurrence of hip fracture. Overall, the incidence of hip fracture among all the women assigned to risedronate was 2.8 percent, as compared with 3.9 percent among those assigned to placebo (relative risk, 0.7; 95 percent confidence interval, 0.6 to 0.9; P=0.02). In the group of women with osteoporosis (those 70 to 79 years old), the incidence of hip fracture among those assigned to risedronate was 1.9 percent, as compared with 3.2 percent among those assigned to placebo (relative risk, 0.6; 95 percent confidence interval, 0.4 to 0.9; P=0.009). In the group of women selected primarily on the basis of nonskeletal risk factors (those at least 80 years of age), the incidence of hip fracture was 4.2 percent among those assigned to risedronate and 5.1 percent among those assigned to placebo (P=0.35). Risedronate significantly reduces the risk of hip fracture among elderly women with confirmed osteoporosis but not among elderly women selected primarily on the basis of risk factors other than low bone mineral density.

30 January 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MMMichael R. McClung
Michael R. McClung
AGAndreas Grauer
Andreas Grauer
SBSteven Boonen
Steven Boonen
MBMichael A. Bolognese
Michael A. Bolognese
JBJacques P. Brown
Jacques P. Brown
HBHenry G. Bone
Henry G. Bone
Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of −2.0 or less at the lumbar spine, total hip, or femoral neck and −3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator — oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.)

24 December 2010 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
FGfor the IOF-IFCC Bone Marker Standards Working Group
for the IOF-IFCC Bone Marker Standards Working Group
SVS. Vasikaran
S. Vasikaran
RER. Eastell
R. Eastell
Olivier BruyèreOlivier Bruyère
Olivier Bruyère
AFA. J. Foldes
A. J. Foldes
JKJ. A. Kanis
J. A. Kanis

23 February 2006 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
MMMichael R McClung
Michael R McClung
ELE Michael Lewiecki
E Michael Lewiecki
SCStanley B Cohen
Stanley B Cohen
MBMichael A Bolognese
Michael A Bolognese
GWGrattan C Woodson
Grattan C Woodson
AGAMG 162 Bone Loss Study Group
AMG 162 Bone Loss Study Group
Receptor activator of nuclear factor-κB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action.

15 March 2005 in Endocrine Reviews
Verified
Journal Article
Closed access
AHAnthony B. Hodsman
Anthony B. Hodsman
DBDouglas C. Bauer
Douglas C. Bauer
DDDavid W. Dempster
David W. Dempster
LDLarry Dian
Larry Dian
DHDavid A. Hanley
David A. Hanley
CYChui Kin Yuen
Chui Kin Yuen
All therapies currently recommended for the management of osteoporosis act mainly to inhibit bone resorption and reduce bone remodeling. PTH and its analog, teriparatide [recombinant human PTH(1-34)], represent a new class of anabolic therapies for the treatment of severe osteoporosis, having the potential to improve skeletal microarchitecture. Significant reductions in both vertebral and appendicular fracture rates have been demonstrated in the phase III trial of teriparatide, involving elderly women with at least one prevalent vertebral fracture before the onset of therapy. However, there is as yet no evidence that the antifracture efficacy of PTH will be superior to the bisphosphonates, whereas cost-utility estimates suggest that teriparatide is significantly more expensive. Teriparatide should be considered as treatment for postmenopausal women and men with severe osteoporosis, as well as for patients with established glucocorticoid-induced osteoporosis who require long-term steroid treatment. Teriparatide should also be considered for the management of individuals at particularly high risk for fractures, including subjects who are younger than age 65 and who have particularly low bone mineral density measurements (T scores < or = 3.5). Teriparatide therapy is not recommended for more than 2 yr, based, in part, on the induction of osteosarcoma in a rat model of carcinogenicity. Total daily calcium intake from both supplements and dietary sources should be limited to 1500 mg together with adequate vitamin D intake (< or =1000 U/d). Monitoring of serum calcium may be safely limited to measurement after 1 month of treatment; mild hypercalcemia may be treated by withdrawing dietary calcium supplements, reducing the dosing frequency of PTH, or both. At present, concurrent therapy with antiresorptive therapy, particularly bisphosphonates, should be avoided, although sequential therapy with such agents may consolidate the beneficial effects upon the skeleton after PTH is discontinued.